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Background: The efficacy and safety profile of ciclesonide (CIC) in the treatment of asthma
was evaluated in a large patient population in a real-life setting in Germany.
Methods: 24,037 patients with persistent mild/moderate bronchial asthma were enrolled into
three observational studies with identical design. Data were pooled and analyzed. Patients
received ciclesonide (160 mg/day) and were observed for 3 months. FEV1, PEF, NO, asthma
episodes, use of rescue medication and adverse drug reactions (ADR) were recorded.
Results: Mean (95% CI) FEV1 significantly increased from 80.7 [80.5; 80.9]% of predicted at
baseline to 90.1 [89.9; 90.2]% after 3 months (n Z 20,297), mean PEF significantly increased
from 338 [335; 340] l/min to 392 [390; 395] l/min (n Z 8100). NO was significantly reduced
from 53.6 [51.8; 55.4] ppb to 26.2 [25.2; 27.1] ppb (nZ 971). The percentage of patients with
daily symptoms declined from 24.3% to 1.9%, night-time symptoms from 13.3% to 1.3%, and b2-
agonists use from 26.9% to 8.8%. ADRs were reported by 51 patients (0.2%). Most frequent ADRs
were: dysphonia (n Z 11), cough (n Z 10), dyspnoea, throat irritation, and oral candidiasis
(n Z 5 each). 46 patients terminated the study prematurely, 41 due to ADR and 5 due to
unknown/missing reason. One patient died due to cardiac failure (no causal relation).
Conclusion: These observational studies under real-life conditions support findings from
controlled clinical studies regarding efficacy and tolerability of ciclesonide in patients with
mild to moderate bronchial asthma. No unexpected ADRs were detected.
ª 2010 Elsevier Ltd. All rights reserved.servational studies conducted in Germany
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Inhaled corticosteroids (ICS) are so far the most effective
controller drugs for patients with asthma.1 Unfortunately, ICS
are generally underused due to lack of compliance, steroid
fear, and concerns about systemic sideeffects.2 ICSof thefirst
and second generation have some limitations, such as a low
systemicbioavailability andapotential for sideeffects suchas
oral candidasis, hoarseness, and dysphonia.2,3 Ciclesonide
shows an improved therapeutic index and pharmacologic
profile and can, therefore, be regarded as the prototype of
a third generation of ICS.4,5 In 2005 ciclesonide was approved
in the European Union for the treatment of mild to severe
persistent asthma in adults, and since 2006 for the treatment
of asthma in adolescents (12 years and older).
Pharmacology of ciclesonide
Ciclesonide is administered using a metered-dose inhaler in
a solution of hydrofluoroalkane propellant that allows for the
production of small, highly respirable particles resulting in
a significant deposition in the lungs.6 Numerous studies have
investigated the pharmacological properties of the lung-
activated ciclesonide demonstrating high local efficacy,
reduced drug load, and a lower potential for local side
effects.6e9 Furthermore, the active ciclesonide formsa lipid-
conjugated depot, which is retained in the lungs, leading to
an increased pulmonary residence time. In addition, 99% of
ciclesonide is bound to plasma proteins and is metabolized
and cleared rapidly by the liver (>99% in the liver), which
reduces the potential for systemic side effects.
Ciclesonide in clinical trials
The efficacy and safety of ciclesonide has been demon-
strated in a number of double-blind, randomized, placebo-
controlled studies10e13 in doses of 80e1280 mg per day. The
safety and tolerability data demonstrated ciclesonide to be
safe in asthma. In comparison to other ICS, it provided
a noticeably enhanced tolerability profile. Local side
effects (candidiasis, pharyngitis, dysphonia) occurred with
a low frequency (<2%),14 whereas other ICS show these side
effects with a frequency of 5e30%.15 The potential for
systemic side effects is reduced due to the high protein
binding and rapid clearance of ciclesonide: this could be
shown using laboratory parameters, such as serum
cortisol.16e18
Real-life medical care
Nowadays, drug research and surveillance after author-
isation becomes more and more important. As efficacy is
only checked once, at the time of authorisation, critical
voices have been raised over the years, that there should
be the possibility to monitor also drug efficacy and not only
safety post-authorisation in real world populations and
real-life conditions. Several international guidelines for
Good Epidemiological Practice (GEP) were published by the
U.S. Food and Drug Administration (FDA) and various soci-
eties for epidemiology19e21 laying down the basic principlesof good epidemiological practice. In this context, the FDA
encourages sponsors to consider all methods to evaluate
a particular safety signal, including non-randomized
observational studies of the product’s use in the “real-
world”. The non-interventional studies [NIS], which include
Anwendungsbeobachtungen (AWB) as the most common
form in Germany, are considered as effective instruments
for assessing safety of a medicinal product and for con-
firming the results obtained in randomized clinical trials. In
early 2007 then, the German Association of Research-Based
Pharmaceutical Companies (VFA) consolidated the essential
elements of NIS, that ensure high quality standards.22 In
2008, the Brussels Declaration of Asthma urged the funding
of “real-world” studies and supported that the results
should be used to inform treatment guidelines.23,24 Many
studies of this type have been performed with various
compounds in asthma either retrospectively e.g.25e27 or
prospectively e.g..28e31
For the first time, the use of ciclesonide was investigated
in three non-interventional cohort studies, all designed to
assess the tolerability and efficacy of ciclesonide in routine
medical practice. The focus of the present analysis is on the
pooled tolerability and efficacy data of these three non-
interventional trials that were performed after approval and
market introduction of ciclesonide (Trade name: Alvesco)
in 2005 in a time period between February 2006 and
December 2007. The acyronyms of the studies were BASIS
(Basistherapie bei Asthma mit Alvesco), ATALL (Alvesco
fu¨r die Therapie des persistierenden Asthma mit/ohne
allergischer Komponente), and ART (Alvesco fu¨r die Ther-
apie des persistierenden und/oder allergischen Asthmas).
These large-scale studies included more than 24,000 patients
with mild to moderate persistent asthma treated with
ciclesonide over 3 months in Germany.
Methods
Study design and study period
Three prospective, multicenter, open-label, observational
studies were conducted in accordance with the recommen-
dations of theGermanFederal Institute forDrugs andMedical
Devices (BfArM) on observational studies (x67 section 6
German Drug Law) and national sickness fund associations in
Germany (BKK) on behalf of Nycomed Deutschland Ltd
(former Altana Pharma Deutschland GmbH), who is the
authorisation holder for marketing of Alvesco. According to
the EU Directive 2001/20/EG article 2c and x 4 German Drug
Law, non-interventional studies (NIS) are studies where
“findings from the treatment of personswith drugs according
to the terms of the marketing authorisation are analyzed
with epidemiologicalmethods; thereby treatment, including
diagnosis and control, does not follow any predefined study
plan but only the medical practice. Hence, NIS are not
subject of the conditions of xx10, 40, 41, and42GermanAMG,
and no ethics committee approval was mandatory at that
time.32,33
Investigators were pneumologists, specialists in internal
medicine or general practitioners that were selected on the
basis of their experience in conducting non-interventional
studies. As the studies were designed to reflect the current
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ralistic setting, all treatment decisions were left to the
discretion of the investigator. The diagnosis was confirmed
by standard lung function evaluation procedures, i.e.
assessment of forced expiratory volume in 1 second (FEV1),
peakflow measurement (PEF) and frequency of day- and
night-time symptoms, according to the guideline of the
German Respiratory Society and the German airway league
(Deutsche Atemwegsliga, 2005).
Severity of asthma was graded accordingly, with patients
having mild persistent asthma if FEV1 was 80% of the
predicted value, PEF-variability 20e30%, frequency of
daytime symptoms >1 per week, but < 1 per day, and
night-time symptoms >1 per week. Asthma was diagnosed
as being of moderate severity if FEV1 was 60e80% of the
predicted value, PEF-variability 20e30%, frequency of
daytime symptoms daily, and night-time symptoms >1 per
week. Study design and all details for implementation of
the studies were defined in the respective study protocols.
Only those data were documented that are routinely
assessed in the diagnosis and treatment of asthma.
Patients were recruited independently from their
cultural background, age, or socioeconomic status, and
informed by the investigator about the study. Patients were
followed up for a period of 3 months. The studies were
conducted between February 2006 and December 2007
(duration per study 9, 10, and 20 months, respectively).
The trials were identical in scope and design so that data
could be pooled and analyzed.
Inclusion criteria
The studies included male and female patients (12 years and
older) with a diagnosis of persistent asthma of mild to
moderate severity who newly started or switched to treat-
ment with ciclesonide. No further inclusion or exclusion
criteria were specified. As with all inhaled corticosteroids,
patients with the following contra-indications for treatment
with ICS as stated in the Summary of Product Characteris-
tics,34 were not included in the studies: patients with active
or quiescent pulmonary tuberculosis, fungal, viral or bacte-
rial infections (only if these patients were adequately
treated), and patients with status asthmaticus or other
acute episodes of asthma where intensive measures are
required. Further, ciclesonide is contraindicated in patients
with a hypersensitivity to any of its ingredients.
Assessments
Data were collected at an initial baseline visit and after 3
months. At the initial visit, the investigator documented
demographic data, medical history, and disease-related
information, including duration of asthma and current
medication, further respiratory and other concomitant
diseases (e.g. hypertension, diabetesmellitus, osteoporosis,
allergies), concomitant medication and smoking status.
Visits included standard spirometry, i.e. FEV1 (total and
percentage of predicted value), mean PEF, and exhaled
nitric oxide (NO) (only documented in BASIS and ATALL), as
well as an assessment of the frequency of daytime (<1 per
week, 1 per week but not daily, daily) and night-timeasthma episodes (2 per month, >2 per month, 1 per week,
>1 per week), as reported by the patient. Further, adverse
drug reactions (ADRs) were collected the following way: in
cases that patients spontaneously reported an adverse drug
reaction, investigators had to fill in an ADR documentation
form to be submitted to the sponsor and/or the authorities.
Further, the impact of an acute worsening of symptoms on
the quality of sleep during the previous month was evalu-
ated. In addition, the use of rescue medication (short-or
long-acting b2-sympathomimetics) was recorded (none,
daily, 2 per week, 2 per week) by the physician.
Uncontrolled asthma was defined according to GINA
criteria. Patients were assessed as uncontrolled by the
physician if they met these criteria. All ADRs were docu-
mented in detail in a special section of the case report form
and transferred to a clinical research organisation (CRO;
Medidata, Konstanz, Germany). Serious ADR as well as
incidences of overdose regardless of outcome were repor-
ted immediately to the CRO. At the final visit, the investi-
gators repeated the questioning of ADR, spirometry, NO,
and symptom assessments.Sample size considerations and statistics
It was planned to enrol 4000 (BASIS), 12,000 (ATALL), and
16,000 patients (ART) into the studies. This sample size was
calculated assuming that a rare adverse drug reaction could
be observed at least once with an incidence of 0.1%
(resulting in a sample size of 4.000 patients), 0.03% (12.000
patients), and 0.02% (16.000 patients), with an a Z 0.05,
assuming binomial distribution. This assumption is in
accordance with current guidelines on the use of statistical
signal detection methods in the eudravigilance data anal-
ysis system.35
The primary objective of the studies was the change in
spirometry-derived FEV1 from baseline to study end, as well
as improvement of symptoms as rated by the investigator.
Other endpoints included evaluation of tolerability as
assessed by spontaneous reporting of adverse drug reac-
tions, handling of ciclesonide and changes of need for
rescue medication.
The statistical analysis of the study results was performed
according to a statistical analysis plan. Data entry and anal-
yses were carried out by MEDIDATA Inc., Konstanz, Germany,
using the statistical software package SAS. Entry of medica-
tions and diseases was supported by thesaurus files. Medi-
cations were analyzed on the basis of International
Nonproprietary Name (INN) listing. Before start of analysis,
plausibility checks were performed and errors were cor-
rected. The analyses were exploratory, no confirmatory
statistical tests were performed, and no confirmatory
statements derived. For the parameters, FEV1, PEF and NO,
the 95% confidence intervals of the means were calculated.
Continuous variables were summarized using descriptive
statistics (number of patients, mean, median, SD, range and
binary or categorical variables using frequency distribution
tables as appropriate). Adverse drug reactions (ADRs) were
analyzed descriptively (number of events and corresponding
95% confidence intervals with coding according to Medical
Dictionary for Regulatory Activities (MedDRA). Furthermore,
95% confidence intervals of the means were calculated. A
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values could then be concluded if the 95% two-sided confi-
dence intervals were not overlapping, which corresponds to
a conservative two-sided test at the 5% level.
Administration of ciclesonide
All treatment decisions were solely left to the discretion of
the investigator, i.e. choice of dose as well as concomitant
rescue medication (short- or long-acting b2-sympatho-
mimetics). As stated in the summary of the European
product characteristics (Alvesco), the recommended dose
of ciclesonide is 160 mg once daily, which leads to asthma
control in the majority of patients. Dose reduction to 80 mg
once daily may be an effective maintenance dose for some
patients. It is recommended to administer ciclesonide in
the evening. The final decision on evening or morning
dosing was left to the discretion of the physician. Once
symptom control is achieved, the dose of Alvesco could be
individualised and titrated to the minimum dose needed.
Results
Patient population and course of the studies
A total number of 4401 (BASIS), 8280 (ATALL), and 11,356
patients (ART) were enrolled into the studies, hence, data
from 24,037 patients were pooled for analysis. The origi-
nally planned sample size of a total of 32,000 patients could
not be reached due to slow patient recruitment. A total of
6236 study centers participated in the studies. Of all
patients included in the studies, 90.3% (n Z 21,695)
completed the studies according to the protocol, and 1.9%
(n Z 465) discontinued the treatment with ciclesonide
prematurely (7.8% patients (n Z 1877) with missing data).
The most common reasons for premature discontinuation
(>5% of entries) were recovery from their symptoms
(n Z 202), patient decision or non-compliance (n Z 90),
lack of need for maintenance treatment (n Z 60), insuffi-
cient efficacy (n Z 57), change to other medication
(n Z 46), and adverse drug reactions (n Z 41).
The data quality was acceptable within the present
capabilities of observational studies, which is, among
others, reflected by the number of missing data: The
frequency of missing data with respect to key parameters
were in the range of 1.2% and 3.8%. Regarding demographic
patient characteristics data was missing in 0.3%e16.5%
(depending on the parameter) of cases.
Patient population
Of all patients included in the studies, 55% were female
(n Z 13,228), the mean (SD) age was 46.3  16.8 years
(range 6e102 years) (Table 1). Although ciclesonide is
approved for patients of 12 years and older, also 20 children
(0.08%) at the age of 6e11 years were treated with cicle-
sonide and documented.
Patients suffered from asthma for 7.7 years (8.5 years;
median 5 years). Based on the spirometric data and the
symptom assessment at the start of the observation period,
the severity of asthma was classified as mild in 51.3%(nZ 12,333), moderate in 44.6% (nZ 10,712), and severe in
1.5% (nZ356)ofallpatients (missingdata:2.6%(nZ626)).Of
those 356 patients with severe asthma, 44.1% were smokers
(nZ 118) or ex-smokers (nZ 39) and 53.1%werenon-smokers
(nZ 189; nZ 10withmissing data). A total of 4.7% (nZ 1119)
of the study population additionally suffered from other
respiratory diseases, whereas 95.3% (nZ 22,918) of the study
population did not. Among these, cold (n Z 282) and bron-
chitis (nZ 198) occurred most frequently. A total of 23.8% of
patients (nZ 5710) were smokers and 9.8% (nZ 2357) were
ex-smokers.
The most frequent concomitant diseases were allergies
(68.6%, n Z 5383), hypertension (24.6%, n Z 5911), and
ophthalmological disorders (10.8%, n Z 847).
At study entry, 69.5% of the patients took short-acting b2-
agonists and 24.0% long-acting b2-agonists as concomitant
medication;22.3%didnot takeanyconcomitantmedicationor
had missing data. Other medication for the treatment of
asthma was taken by 10.5% of patients, with montelucast,
theophylline and tiotropiumbromide being used most
frequently (19.7%, 19.0%, and 6.3%, respectively).
Due to theobservation that about 25%of thepatientswere
smokers and some of the included individuals were ex-
smokers and based on the fact that the use of tiotropium-
bromide was observed in about 6% of patients it cannot be
excluded that a proportion of the patients also suffered from
chronic obstructive pulmonary disease (COPD).
55.5% (nZ 13,335) of the study populationwas treatment-
naı¨ve at study start, and 41.5% (nZ 9977) have been treated
previously with other ICS. Budesonide (58.5%, nZ 5838) was
prescribed most frequently, followed by beclometasone
(17.0%, nZ 1693) and fluticasone (14.6%, nZ 1454). Most of
the pre-treated patients took the ICS as monotherapy (bude-
sonide: 89.7%, beclometasone 88.8%, fluticasone 78.8%), all
others in combination with other drugs.
Treatment with ciclesonide
The mean (SD) duration of treatment observation from
baseline to final visit was 13.0 3.7weeks. The vastmajority
of the patients (91.7% (n Z 22,040)) were started on the
recommended dose of 160 mg per day (i.e. 1 puff), and 5.9%
(nZ 1408) of the patients were started on 2 times 160 mg per
day. At the final visit, 91.8% (n Z 22,073) of patients were
treated with 160 mg/day (at baseline: 91.7%), 3.1% (nZ 757)
with 2  160 mg/day (at baseline: 5.9%), and 1.0% (nZ 242)
with 80 mg/day (at baseline: 0.5%).
Efficacy
Lung function
With regard to the efficacy endpoint the mean [95% confi-
dence interval (CI)] FEV1-value significantly increased
during the observational period from 2.66 [2.65; 2.67] l to
3.00 [2.99; 3.01] l, i.e. increased by 9.4% from 80.7 [80.5;
80.9]% to 90.1 [89.9; 90.2]% predicted (Fig. 1) as indicated
by non-overlapping 95% confidence intervals. The mean PEF
was assessed in 8100 patients at both initial and final visit.
In these patients, a significant increase in PEF of 14%, i.e.
from 338 [335; 340] l/min to 392 [390; 395] l/min could be
observed (non-overlapping CIs).
Table 1 Demographic data and patient characteristics at
baseline.
Variable Population
(N Z 24,037)
n (%)
Gender
Male 10,702 (44.5%)
Female 13,228 (55.0%)
Missing data 107 (0.4%)
Age (years)
Mean age (SD) 46.3 (16.8)
Median 46.0
Minimum-Maximum 6.0e102.0
Weight, kg (SD) 76.0 kg (14.6)
Minimum-Maximum 25.0e188.0
Height, cm (SD) 170.8 (9.1)
Minimum-Maximum 114.0e206.0
Duration of asthma
(years)
Mean (SD) 7.7 (8.5)
Median 5.0
Minimum-Maximum 0.042e85.0
Severity
Mild 12,333 (51.3%)
Moderate 10,712 (44.6%)
Severe 356 (1.5%)
Missing data 626 (2.6%)
Smoking status
Smoker 5710 (23.8%)
Ex-Smoker 2357 (9.8%)
Non-Smoker 15,729 (65.4%)
Missing data 241 (1.0%)
Allergies
None 7698 (32.0%)
Missing data 5058 (21.0%)
Allergies, yes 11,281 (46.9%)
Against:
Pollen 8969 (79.5%)
House dust mites 4573 (40.5%)
Animal protein 2203 (19.5%)
Fungal spores 911 (8.1%)
Chemical agents 419 (3.7%)
Othera 234 (2.1%)
Missing data 359 (3.2%)
SD Z standard deviation.
a Other allergenes were: food, medications, metals, plants,
insect poison, gum arabic/latex.
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Figure 1 Improvement of the lung function with once daily
160 mg ciclesonide. Data presented are mean values (standard
deviation) of FEV1 [l] (N Z 19,953) and % of the predicted
value (N Z 20,297) from patients with complete data at both
visits.
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The assessment of NO was performed in 971 patients: The
concentration of NO significantly decreased from 53.6
[51.8; 55.4] ppb to 26.2 [25.2; 27.1] ppb, which represents
a reduction of 51%.
Asthma episodes
The incidence of asthma-related symptoms were reduced
during the course of the study (Fig. 2). The proportion of
patients that suffered from daily symptoms at daytime was
reduced from 24.3% to 1.9% after 3 months of treatmentwith ciclesonide, and the proportion of patients with
symptoms that occurred >1 per week was reduced from
59.4% to 24.4% (Fig. 2a). Accordingly, the number of
patients reporting less frequent symptoms (<1 per week)
increased from 14.1% to 68.9%. A similar improvement
could also be observed for night-time symptoms (Fig. 2b).
Here, the proportion of patients with frequent (>1 per
week) night-time symptoms decreased from 13.3% to 1.3%,
whereas the proportion with only rare night-time episodes
(2 per month) increased from 34.7% to 77.7%.
The number of nights of the preceding month with
nocturnal symptoms decreased from 5.4  5.1 at study start
to 2.5  2.8 after 3 months of treatment.
Quality of sleep
The negative impact of acute worsening of asthma symp-
toms on the quality of sleep was reduced. The proportion of
patients whose quality of sleep was impaired, was 39.8% at
study entry. This proportion was reduced to 8.2% after 3
months of treatment. Vice versa, the proportion of patients
without impaired sleep quality due to worsening of symp-
toms increased from initially 25.4% to 55.7%.
Safety
During the 3 month treatment period, ADRs were reported
in 51 (0.2%) patients, and 46 patients discontinued
therapy, 41 due to ADRs and 5 due to unknown or missing
reasons (Table 2). The 51 ADRs all were considered as
definitely, probably, or possibly related to the treatment.
Most ADRs were of mild or moderate intensity. Most
commonly reported non-serious ADRs (n Z 50) were
dysphonia (n Z 11) and cough (n Z 10). In 1 patient, the
ADR was classified as serious, with fatal outcome due to
mycocardial infarction (no relation to ciclesonide as
assessed by the investigator). Two further patients expe-
rienced serious events, which both were not considered as
drug related: one patient with a cataract and one patient
with a severe anxiety with subsequent hospitalization.
As assessed by the investigator, three of the 50 non-
serious ADRs (6.0%) were considered definitely related to
therapy (strong urge to cough after inhalation, throat
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Figure 2 Reduction of asthma episodes a) during daytime,
and b) during night-time (N Z 24,037).
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and 1 (2.0%) as possible (missing data for 7 ADRs).
Also 20 children at the age of 6e11 years were treated
with ciclesonide and documented. In these patients,
treatment with ciclesonide was well tolerated. One patient
(15 years, female) experienced dysphonia over 20 days with
a probable causal relationship to the treatment, and dis-
continued therapy.
Discussion
For the first time data on the use of ciclesonide in real-life
setting are reported. The results of the present pooled
analysis of three non-interventional, prospective, large-
scale multicenter studies conducted in Germany with over
24,000 patients support the results from previous studies
that therapy with ciclesonide (160 mg once daily) is safe in
patients with persistent mild to moderate asthma also
under conditions of routine clinical care. Considerable
improvement of FEV1, PEF, NO, and asthma symptom
control were observed after 3 months of treatment
compared to baseline. A low incidence of ADRs was
observed (51/24,037 patients, or 0.2%).
The results of the present studies are in accordance with
findings from previously performed randomized, controlled
clinical studies. In the present analysis, mean FEV1 was 9.4%
higher after 3 months, which is in the same range as the
reported median improvement of FEV1 of 11% after 3 months
of treatment with 80 mg ciclesonide once daily ina randomized study.36 A placebo-controlled study by Lang-
don et al. also noted significant improvements in FEV1
(significant increases of þ0.13 l with 80 mg and þ0.19 l with
320 mg ciclesonide versus placebo after 3 months) and PEF in
patients treated with 80 mg or 320 mg daily ciclesonide for 3
months compared to placebo.12Other 3-month, randomized,
double-blind, active controlled studies also demonstrated
a significant increase in FEV1 from baseline to study end with
non-inferiority to budesonide and fluticasone.37e39
Similarly, the mean PEF increased in the course of the
treatment with 160 mg ciclesonide by 14% which is compa-
rable to the previously reported clinical trials with 22.4 l/
min with half the dose.12
In addition, in two of the three non-interventional trials
(BASIS and ATALL) exhaled NO was reduced by 51% in
a subgroup of patients after 3 months of treatment. This is
in accordance with a comparative study investigating the
impact of 3 months treatment with ciclesonide or flutica-
sone on exhaled NO reported by Zietkowski et al., who
found that NO was reduced by 56.4% with 80 mg, and 70.0%
with 160 mg, ciclesonide once daily (fluticasone 100 mg once
daily: 38.2%).30
The improvement of lung function was accompanied by
a reduction of daytime and night-time asthma episodes.
The proportion of patients that suffered from daily asthma
episodes during the daytime was reduced from 24.3% at
study start to 1.9%. Similar results were observed for
frequent asthma episodes during the night-time, with
a reduction from 13.3% to 1.3%. These findings are sup-
ported by the results of numerous randomized, placebo-
controlled studies that demonstrated a significant decline
of day- and night-time asthma episodes after a 3-month
application of 160 mg ciclesonide once daily in children and
adults.39e42 The need for rescue medication is another
important parameter for the assessment of asthma therapy
in routine clinical care. In our analysis, the daily
consumption of b2-agonists decreased from 26.9% at base-
line to 8.8% after 3 months. Significant reductions in rescue
medication use from day 1 after start of ciclesonide
treatment has been reported previously in several
randomized, controlled clinical studies e.g..30,36
Overall, concerning the most relevant parameters, cicle-
sonide supported efficacy data previously shown in random-
ized, controlled trials in smaller patient populations with
more rigid inclusion and exclusion criteria.36,39,40
The incidence of ADRs was low in this large-scale patient
population, with only 51 patients (0.2%) experiencing an
adverse event, compared to an AE incidence rate of about
4% reported in pivotal trials studying ciclesonide at doses
ranging from 80 mg to 1280 mg per day. This low incidence of
ADR might be explained by the non-interventional design of
the studies in which only spontaneously reported ADRs were
documented and not as thoroughly reported as in clinical
trials. Investigators had to fill in a ADR documentation form
to be submitted to the sponsor and/or the authorities. It
cannot be ruled out that investigators only used this form in
case of ADRs that seemed to be unusual to the investigator.
Further, it is well known that ADRs tend to be under-
reported in routine medical care, especially for drugs
recently marketed or for less severe and known side
effects.43,44 Thus, it is likely that in the present observa-
tional studies the absolute number of documented ADRs
Table 2 Most frequent (0.02%) adverse drug reactions reported during the 3-months observational period (N Z 24,037).
Adverse drug reactions (ADRs) Patients, n % 95% CI
Overall ADRs 51 0.2
Non-serious ADRs in 2 patients (MedRA preferred term) 50 0.2
Dysphonia 11 0.05 0.02e0.07
Cough 10 0.04 0.02e0.07
Pregnancy 7 0.03 0.01e0.05
Dyspnoea 5 0.02 0.00e0.04
Oral candidiasis 5 0.02 0.00e0.04
Throat irritation 5 0.02 0.00e0.04
Nausea 2 <0.01 0.00e0.02
Oral discomfort 2 <0.01 0.00e0.02
Stomatitis 2 <0.01 0.00e0.02
Serious ADRs
Myocardial infarction (no relation) 1 <0.01 Exitus
Discontinuing patients 46
ADRs leading to discontinuation with probable or definite causal relation to Ciclesonide
MedRA preferred terma 45 ADRs in 41 patients
Cough 9
Dyspnoea 6
Dysphonia 6
Throat irritation 4
Oral candisiasis 3
Nausea 2
Oral discomfort 2
Stomatitis 2
Chest discomfort, Dry mouth, Eczema,
Gingival disorder, Infection, Insomnia,
Mucosal inflammation, Myalgia, Palpitations,
Pharyngolaryngeal pain, Skin haemorrhage
1 each
ADRs leading to discontinuation with improbable causal relation or missing information
MedRA preferred terma 17 AEs in 5 patients
Pregnancy 4
Cough 3
Anxiety, Cataract, Dyspepsia, Dyspnoea,
Headache, Insomnia, Nausea, Pruritus, Urticaria, Throat irritation
1 each
Abbreviations: ADR Z adverse drug reaction; MedRA Z Medical Dictionary for Regulatory Activities.
a More than one ADR in one patient possible.
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ing seems to be positively selective, one can assume that
serious, severe or rare reactions were still detected in the
present studies.
In the observational studies, the incidence of cough,
dysphonia, and irritations was <0.05%. Oral candidiasis was
reported by 5 out of 24,037 patients. In the summary of
product characteristics of Alvesco an overall ADR inci-
dence rate of about 5% is reported.34 Most of these AEs
were of mild nature and did not lead to discontinuation of
therapy. One death was documented, but was considered
“definitely unrelated” to the prescribed medication.
Observational studies in asthma may provide important
additional data in the “real-world setting” as suggested by
Holgate et al.23 Recently, a study also showed clinically
relevant improvements with montelukast in a largeobservational study28 with 1681 patients with mild to
moderate asthma confirming earlier data from randomized,
controlled studies.Limitations
Observational studies can make an important contribution to
medical knowledge, but naturalistic, non-interventional
study designs generally have a number of limitations. Most
importantly, the studies did not include a placebo arm or an
activecomparator arm, so that thedegree towhich the results
reflect drug-specific effects remains uncertain. This study has
limitations due to the inherent biases introduced by the open-
label design. However, there are plenty of randomized
controlledtrials andmeta-analyses in the literature,whohave
Treatment of asthma with ciclesonide in routine practice 193answered such research questions sufficiently for ciclesonide.
Further, the impact of possible confounding factors have not
been investigated and datawere not evaluated as carefully as
in a randomized clinical trial.
Factors that may bias the results of observational studies
can be broadly categorized as selection bias resulting from
the way study subjects are recruited or from differing rates
of study participation depending on the subject’s cultural
background, age, or socioeconomic status, and information
bias. The studies were not based on an epidemiological
sample, but on a sample recruited by investigators who
were willing to participate in this observational trial.
Hence, unspecific factors such as rater bias, expectation
effects, and time effects cannot be ruled out. Furthermore,
the studies were carried out exclusively in Germany. Thus,
the results may not be generalizable to countries with other
health care systems. Furthermore, the number of ADRs
reported was surprisingly low with only 51 of the 24,037
patients experiencing an ADR. Presumably, this is also
a consequence of the non-interventional design in which
data are not thoroughly reported as in monitored clinical
trials. One further limitation is the result of incomplete
recording of data regarding medication-naı¨ve and pre-
treated patients. Therefore, analyses were not possible in
this respect. Also, only two visits (at start and at 3 months)
were scheduled, hence, no information about compliance/
adherence and about speed of onset of action could be
derived from the data. It should also be mentioned that not
everything was "real-life" in the studies. In particular, the
decision to start ciclesonide instead of another inhalation
corticosteroid may have been influenced by the fact that
this study with a new molecule was running with priority on
the department.
One of the strengths of this pooled analysis of three non-
interventional trials, however, is the large sample size of over
24,000 patients drawn from over 6000 private practices. This,
and the observation period of 3 months, makes it more likely
that a rare ADR would be detected. In addition, the many
participating centres and patients can be regarded as repre-
sentative for the primary health care situation in Germany,
although recruitment was not as strict as in epidemiological
investigations. Therefore, these observational studies,
particularly large ones, provide extensive and useful infor-
mation about treatment outcomes in daily medical practice.
Conclusions
The pooled results from these three observational studies
in a large patient population of more than 24,000 patients
with mild to moderate bronchial asthma support the find-
ings from clinical trials that ciclesonide is efficacious and
well tolerated, also in a routine clinical care setting and
that ciclesonide is suitable for use in the first-line therapy
of asthma.
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